SM
CRXT

Sabby Management’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Sabby Management’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-146,900
Closed -$5K – 139
2022
Q3 		$5K Sell
146,900
-53,100
-27% -$16.3K 0.01% 113
2022
Q2 		$76K Buy
+200,000
New +$140K 0.05% 91

Sabby Management's CRXT Position: Q4 2022 in Review

Sabby Management sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q4 2022, closing a stake of 146,900 shares — an estimated $5K sold.

Sabby Management first reported a position in CRXT in Q2 2022 and held it in 2 quarters. The position peaked at $76K in Q2 2022. 0 funds tracked by Wall St. Rank hold CRXT as of Q4 2022.

  • Sabby Management reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Sabby Management sold 146,900 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $5K.
  • Sabby Management first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Sabby Management's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $76K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Sabby Management's 13F filing for Q4 2022, filed 14 Feb 2023.